COST-EFFECTIVENESS AND COST-UTILITY OF HIGH-DOSE INACTIVATED INFLUENZA VACCINE VERSUS STANDARD-DOSE INACTIVATED INFLUENZA VACCINE IN THE OLDER ADULTS AGED =65 YEARS IN POLAND
Author(s)
Arvind Bhushan, MBA1, Marta Nowak, MSc2, Gerald Moncayo, PhD3.
1HEVA Vaccines, Sanofi, Hyderabad, India, 2Vaccines, Sanofi, Warsaw, Poland, 3Vaccines, Sanofi, Lyon, France.
1HEVA Vaccines, Sanofi, Hyderabad, India, 2Vaccines, Sanofi, Warsaw, Poland, 3Vaccines, Sanofi, Lyon, France.
OBJECTIVES: Influenza poses a substantial clinical burden in older adults (aged ≥65 years), with an increased risk of complications, hospitalization, and death. High-dose inactivated influenza vaccine (HD-IIV) has demonstrated superior immunogenicity and clinical effectiveness compared with standard-dose inactivated influenza vaccine (SD-IIV) in older adults. This study evaluated the cost-effectiveness of HD-IIV versus SD-IIV influenza vaccination strategies among older adults aged ≥65 years in Poland from the healthcare perspective.
METHODS: A validated decision-analytic influenza model was adapted using Polish-specific inputs for each vaccination strategy over one influenza season. Clinical inputs were derived from randomized controlled trials and published real-world evidence. The model estimated influenza cases, general practitioner (GP) visits, hospitalizations, deaths, quality-adjusted life years (QALYs), and associated costs. The base case considered hospitalizations conditional on influenza. Incremental cost-effectiveness ratios (ICERs) were expressed as Polish złoty (PLN) per QALYs gained. Sensitivity analyses explored variations in parameters.
RESULTS: In the influenza specific base case, implementing HD-IIV instead of SD-IIV averted 14,719 influenza cases, 5,417 GP visits, 570 hospitalisations, and ~190 deaths, resulting in gains of 1,719 life-years (LYs) and 1,465 QALYs. The ICER was PLN 85,090 per LY gained and PLN 99,834 per QALY gained, below the WHO-recommended threshold of PLN 244,821 (3 times GDP per capita). Sensitivity analyses confirmed robustness, with results most sensitive to relative efficacy of HD-IIV versus SD-IIV, HD-IIV vaccine cost, and influenza-attributable mortality
CONCLUSIONS: HD-IIV is a cost-effective strategy over SD-IIV for older adults aged ≥65 years in Poland. Notably, expansion of the analytical scope to include cardiorespiratory benefits would be anticipated to generate significantly lower ICERs, thereby improving the overall cost-effectiveness profile. These findings could guide payers in evaluating HD-IIV for inclusion in Poland's immunization strategy, potentially improving health outcomes in older adults aged ≥65 years.
METHODS: A validated decision-analytic influenza model was adapted using Polish-specific inputs for each vaccination strategy over one influenza season. Clinical inputs were derived from randomized controlled trials and published real-world evidence. The model estimated influenza cases, general practitioner (GP) visits, hospitalizations, deaths, quality-adjusted life years (QALYs), and associated costs. The base case considered hospitalizations conditional on influenza. Incremental cost-effectiveness ratios (ICERs) were expressed as Polish złoty (PLN) per QALYs gained. Sensitivity analyses explored variations in parameters.
RESULTS: In the influenza specific base case, implementing HD-IIV instead of SD-IIV averted 14,719 influenza cases, 5,417 GP visits, 570 hospitalisations, and ~190 deaths, resulting in gains of 1,719 life-years (LYs) and 1,465 QALYs. The ICER was PLN 85,090 per LY gained and PLN 99,834 per QALY gained, below the WHO-recommended threshold of PLN 244,821 (3 times GDP per capita). Sensitivity analyses confirmed robustness, with results most sensitive to relative efficacy of HD-IIV versus SD-IIV, HD-IIV vaccine cost, and influenza-attributable mortality
CONCLUSIONS: HD-IIV is a cost-effective strategy over SD-IIV for older adults aged ≥65 years in Poland. Notably, expansion of the analytical scope to include cardiorespiratory benefits would be anticipated to generate significantly lower ICERs, thereby improving the overall cost-effectiveness profile. These findings could guide payers in evaluating HD-IIV for inclusion in Poland's immunization strategy, potentially improving health outcomes in older adults aged ≥65 years.
Conference/Value in Health Info
2026-11, ISPOR Europe 2026, Vienna, Austria
Value in Health, Volume 29, Issue 12S
Code
EE746
Topic
Economic Evaluation, Epidemiology & Public Health, Health Technology Assessment
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies
Disease
No Additional Disease & Conditions/Specialized Treatment Areas, Vaccines